New drug may help keep esophageal cancer at bay after standard treatment
NCT ID NCT07246330
First seen Nov 25, 2025 · Last updated Jun 19, 2026 · Updated 31 times
Summary
This Phase 3 trial tests whether the immunotherapy drug toripalimab can help prevent cancer from growing in people with advanced esophageal cancer who have already received chemotherapy and radiation. About 340 participants will be randomly assigned to receive toripalimab or just be observed. The study aims to see if toripalimab improves the time before the cancer progresses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Toripalimab (a drug that helps the immune system fight cancer)
What this could lead to
If successful, this could provide a new treatment option to delay cancer progression in patients with advanced esophageal cancer.
What could go wrong
This is a Phase 3 trial, but results are not yet available. The drug may not improve outcomes for all patients and could cause side effects like immune-related reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.